产品库

CRL-2922 EA.hy926 人脐静脉细胞融合细胞

产品信息

  • 简单介绍
    CRL-2922 EA.hy926 人脐静脉细胞融合细胞,ATCC 细胞|细胞系|细胞株|肿瘤细胞|细胞;细胞库管理规范,提供的细胞株背景清楚,提供参考文献和培养条件!

    CRL-2922 EA.hy926 人脐静脉细胞融合细胞 的详细介绍
    CRL-2922 EA.hy926 人脐静脉细胞融合细胞
    ATCC® Number: CRL-2922™    Price:
    Designations: EA.hy926
    Depositors:  CS Edgell
    Biosafety Level: 1
    Shipped: frozen
    Medium & Serum: See Propagation
    Growth Properties: adherent
    Organism: Homo sapiens (human)
    Morphology: endothelial
    Source: Tissue: somatic cell hybrid
    Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
     
    Restrictions: For-profit institutions must obtain license from University of North Carolina, Chapel Hill.
    Antigen Expression: Factor VIII-related antigen; Homo sapiens, expressed
    DNA Profile (STR): Amelogenin: X
    CSF1PO: 10,11,12
    D13S317: 11
    D16S539: 11,12
    D5S818: 11
    D7S820: 8,9,10
    THO1: 6,8,9.3
    TPOX: 8,9
    vWA: 14,17
    Comments: The human umbilical vein cell line, EA.hy926, was established by fusing primary human umbilical vein cells with a thioguanine-resistant clone of A549 by exposure to polyethylene glycol (PEG). Hybrid clones were selected in HAT medium and screened for factor VIII-related antigen. EA.hy926 cells have been maintained for more than 100 population doublings (PDLs). Electron photomicrographs demonstrate cytoplasmic distribution of Weibel-Palade bodies and tissue-specific organelles, characteristics of differentiated endothelial cell functions such as angiogenesis, homeostasis/thrombosis, blood pressure and inflammation. [PubMed: 6407019] [PubMed: 2079463]
    Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10.
    Atmosphere: air, 95; carbon dioxide (CO2), 5
    Temperature: 37.0°C
    Subculturing: Protocol: Volumes used in this protocol are for 75 sq cm flasks; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
    1. Remove and discard culture medium.
      • Briefly rinse the cell layer with Ca++/Mg++ free Dulbeccos phosphate-buffered saline (D-PBS) or 0.25 (w/v) Trypsin - 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
        • Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
          Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37C to facilitate dispersal.
          • Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
            • Transfer cell suspension to a centrifuge tube and spin at approximately 125 X g for 5 to 10 minutes. Discard supernatant.
              • Resuspend the cell pellet in fresh growth medium. Add appropriate aliquots of the cell suspension to new culture vessels. An inoculum of 2 X 10(3) to 3 X 10(3) viable cells/sq. cm is recommended.
                • Incubate cultures at 37C. Subculture when cell concentration reaches between 8 X 10(4) and 1 X 10(5) cells/sq. cm.
                  Interval: Twice a week
                  Subcultivation Ratio: A subcultivation ratio of 1:6 to 1:10 is recommended
                  Medium Renewal: Every 2 to 3 days
    Preservation: Freeze medium: Complete Growth medium, 95; DMSO, 5
    Storage temperature: liquid nitrogen vapor phase
    Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
    recommended serum:ATCC 30-2020
    0.25 (w/v) Trypsin - 0.53 mM EDTA in Hank BSS (w/o Ca++, Mg++):ATCC 30-2101
    phosphate-buffered saline:ATCC 30-2200
    Cell culture tested DMSO:ATCC 4-X
    Erythrosin B vital stain solution:ATCC 30-2404
    Trypan Blue vital stain solution:ATCC 30-2402
    References: 92902: Edgell CJ, et al. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc. Natl. Acad. Sci. USA 80: 3734-3737, 1983. PubMed: 6407019
    92903: Bauer J, et al. In vitro model of angiogenesis using a human endothelium-derived permanent cell line: contributions of induced gene expression, G-proteins, and integrins. J. Cell. Physiol. 153: 437-449, 1992. PubMed: 1280276
    92904: Edgell CJ, et al. Endothelium specific Weibel-Palade bodies in a continuous human cell line, EA.hy926. In Vitro Cell. Dev. Biol. 26: 1167-1172, 1990. PubMed: 2079463
    92905: Rieber AJ, et al. Extent of differentiated gene expression in the human endothelium-derived EA.hy926 cell line. Thromb. Haemostasis 69: 476-480, 1993. PubMed: 8322270

     
  • 信息声明:本产品供应信息由仪器网为您整合,供应商为(上海桑戈生物科技有限公司),内容包括 (CRL-2922 EA.hy926 人脐静脉细胞融合细胞)的品牌、型号、技术参数、详细介绍等;如果您想了解更多关于 (CRL-2922 EA.hy926 人脐静脉细胞融合细胞)的信息,请直接联系供应商,给供应商留言!
    供应商产品推荐
      您可能感兴趣的产品